Navigation Links
Roche to Expand Coagulation Testing Portfolio, Develop New Systems for Diagnostic Laboratories in US and Canada by 2014
Date:10/4/2011

INDIANAPOLIS, Oct. 4, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced plans today to expand its coagulation testing product line in North America beyond physician offices and outpatient clinics with the development of a full line of coagulation analyzers for hospital and reference laboratories. The new line is expected to be introduced in the U.S. and Canada in 2014, subject to regulatory approval and other requirements.

Roche Diagnostics is the global market leader in coagulation (blood clotting) testing at the point of care, offering the CoaguChek® line of handheld meters for use by healthcare professionals and patients. The new line of analyzers for the central coagulation lab, which will be marketed under Roche's cobas® brand, is expected to include three platforms that address a range of customer needs, from low-volume testing to the high-throughput demands of commercial laboratories, along with a complete menu of coagulation assays.

The announcement follows the statement earlier today that, effective January 1, 2012, Roche Diagnostics and Diagnostica Stago will pursue separate paths in laboratory coagulation in territories where Roche distributes the Stago line of lab coagulation analyzers. Roche does not currently distribute Stago products in the U.S. or Canada, so the introduction of the new lab coagulation product line will represent a significant move into a new market for Roche in both countries.

Laboratory coagulation is estimated to be the fifth largest market in professional diagnostics worldwide, representing approximately $1.3 billion in sales in 2010 and having a projected annual growth rate of 5.1% over the next five years.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-diagnostics.us.

COAGUCHEK and COBAS are trademarks of Roche. All trademarks mentioned in this release are protected by law.

For further information, please contact:

Betsy Cox
Director, Corporate Communications
Roche Diagnostics Corporation
Indianapolis, Indiana USA
(317) 521-3911
betsy.cox@roche.com

Melanie Lussier
Associate Manager, Communications
Roche Diagnostics Canada
Laval, Quebec, Canada
(450) 686-3137
melanie.lussier@roche.com


'/>"/>
SOURCE Roche Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Roche Opens New Center of Excellence Facility
2. Roche Diagnostics Supports Fight Against MRSA as a Sponsor of Annual World MRSA Day on October 1
3. Pfizer Overtakes GSK but Trails Roche in PharmaDeals Corp-METRx Analysis of Deal Activity
4. Roche Starts Early Stage Clinical Trial in Down Syndrome
5. Roche Diabetes Care Celebrates Second Annual Infusion Site Awareness Week, Aug. 29-Sept. 4
6. Rochester Medical Reports Fiscal 2011 Third Quarter Results
7. Rochester Medical Announces Third Quarter 2011 Earnings Conference Call Thursday, July 28, 2011
8. Roche NimbleGen and Caliper Collaborate to Offer Automated Target Enrichment Pipeline Solution for Next-Generation Sequencing
9. In Support of the International Day of the African Child, Roche Hosts Annual Childrens Walk
10. Deadly E. Coli Strain Sequenced With Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date
11. Roche and Clovis Oncology to Co-Develop EGFR Companion Diagnostic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... Colo. , July 26, 2017 E.I. ... Guttridge and the Bimini SharkLab to custom design the worlds ... images of sharks in their native habitat. In preparation ... Discovery Channel,s Shark Week, Dr. Guttridge approached EIMI ... take pregnancy diagnosis directly to hammerhead sharks underwater. ...
(Date:7/26/2017)... 2017 The Galien Foundation announced today ... USA Award Nominees. Counted among the global health ... outstanding biomedical and technology product achievement that improves the human ... each candidate must be U.S. Food and Drug Administration (FDA) ... tremendous potential to impact human health. Sales data are not ...
(Date:7/24/2017)... -- IBM (NYSE: IBM ) has been recognized as ... (SSA) for the fourth year in a row. 1 ... in the Leaders quadrant have the highest scores for their ... the Leaders quadrant has the market share, credibility, and marketing ... technologies. These vendors demonstrate a clear understanding of market needs; ...
Breaking Medicine Technology:
(Date:8/16/2017)... NJ (PRWEB) , ... August 16, 2017 , ... With low back pain afflicting 8 ... know what causes its kissing cousin – upper back pain. But this equally vexing condition ... treatment options, according to Kaixuan Liu, MD, PhD , founder and president of Atlantic ...
(Date:8/16/2017)... ... 2017 , ... “Mom, God's Got This: Jamie's Story” is the creation of published author, Karen ... has an insatiable appetite for God’s Word. , “I froze between the half walls, shelves ... packages of oatmeal. I have one to this day on proud display in my dining ...
(Date:8/15/2017)... Buffalo, NY (PRWEB) , ... August 15, 2017 , ... ... as maintenance treatment for multiple myeloma has been completed, with the team’s findings now ... Philip L. McCarthy, MD , Director of the Blood and Marrow Transplant Program at ...
(Date:8/15/2017)... MD (PRWEB) , ... August 15, 2017 , ... ... from BB&T. Horizon Goodwill CEO, John McCain said, “We are overwhelmed with gratitude ... and create opportunities for people who need assistance to both get a job ...
(Date:8/15/2017)... ... 15, 2017 , ... The V Foundation for Cancer Research, ... Foundation Wine Celebration raised nearly $9 million for cancer research during a full ... donations to support the study of BRCA mutation research in laboratories and clinics ...
Breaking Medicine News(10 mins):